Catalyst Biosciences is harnessing the catalytic power of engineered human proteases to develop next-generation biopharmaceuticals with improved efficacy and safety in the fight against major diseases. Focused on drug discovery for hemostasis and complement-driven diseases, age-related macular degeneration and inflammation, Catalyst Biosciences engineers human proteases that initiate or regulate protease driven biological cascades and can inactivate hundreds to thousands of disease-causing target molecules.

Research Grants show all

NIH1

Publications show all

Catalyst Biosciences has published 1 articles.

Patents show all

121Applications108Issued

Clinical Trials show all

1Phase 1

SEC Filings show all

D7

Private Funding Events

DateOfferedSoldType
2015-02-03$5,000,000$3,224,993Equity
2014-04-23$5,009,841$5,009,841Equity, Option to Acquire
2013-08-20$800,008$400,004Equity
2012-09-25$18,593,361$13,407,658Equity
2008-12-08$40,399,998$40,399,998Equity
2007-12-17UnknownUnknownOther (Paper Filing)

Key Executives

  • Nassim Usman
    Executive Officer, Director
  • Barry Selick
    Director
  • Steve Burrill
    Director
  • Ralph Christoffersen
    Director
  • Augustine Lawlor
    Director
  • Asish Xavier
    Director
  • Jeff Himawan
    Director
  • Erik Wiberg
    Executive Officer
  • Edwin Madison
    Executive Officer
  • Todd Lorenz
    Executive Officer
  • Harold E. Selick
    Director
  • Michael Powell
    Director
  • Harold Selick
    Director
  • Steven Burrill
    Director